Drug Safety and Effectiveness Network
The Drug Safety and Effectiveness Network (DSEN) is no longer accepting query requests. Effective September 1st, 2022, queries can be submitted to the Post-Market Drug Evaluation (PMDE) program at the Canadian Agency for Drugs and Technologies in Health (CADTH).
Questions regarding the Drug Safety and Effectiveness Network can be submitted to CIHR by email at: DSEN-RIEM@cihr-irsc.gc.ca.
In Canada and worldwide, there are gaps in information on the safety and effectiveness of drugs used in real-world settings. More information is needed on the safety and effectiveness of pharmaceuticals when used by diverse patient populations outside the controlled experimental environment of clinical trials.
CIHR established the Drug Safety and Effectiveness Network (DSEN) in collaboration with Health Canada and other stakeholders.
DSEN's key objectives are to increase the:
- evidence on drug safety and effectiveness available to regulators, policy-makers, health care providers and patients
- capacity within Canada to undertake high-quality post-market research in this area
- Date modified: